Wendy Mcdermott
Responsable des Ressources Humaines chez LEXICON PHARMACEUTICALS, INC.
Fortune : 81 149 $ au 30/04/2024
Postes actifs de Wendy Mcdermott
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Responsable des Ressources Humaines | 01/01/2022 | - |
Historique de carrière de Wendy Mcdermott
Anciens postes connus de Wendy Mcdermott
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Sanofi Corp. | Responsable des Ressources Humaines | 01/01/2017 | 01/01/2019 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Responsable des Ressources Humaines | 01/01/2019 | - |
Formation de Wendy Mcdermott
| State University of New York College at Plattsburgh | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Sanofi Corp. |
- Bourse
- Insiders
- Wendy Mcdermott
- Expérience